Pulmonary Vein Isolation in Patients with Atrial Fibrillation: What Did We Learn from the SHAM Ablation Studies?

Abstract Purpose of Review This review summarizes the findings and key lessons from sham-controlled trials of pulmonary vein isolation (PVI) in atrial fibrillation (AF). Recent Findings SHAM-PVI, PFA-SHAM, and PVI-SHAM-AF demonstrated lower AF recurrence and burden after PVI compared with sham. Quality of life improved after PVI in all trials, but PVI-SHAM-AF did not show superiority over sham because of similar improvements with sham, reflecting the contribution of nonspecific treatment effects such as expectancy, clinical attention and the Hawthorne effect. The trials demonstrate that invasive sham-controlled studies are feasible, safe, and can achieve blinding. Summary Reductions in AF recurrence and burden with PVI do not consistently translate into greater improvements in quality of life than sham. The contribution of nonspecific treatment effects may have been underestimated in previous trials. Further studies should characterize the relationship between AF burden and symptoms and identify patients most likely to derive symptomatic benefit from PVI.

Authors

Institutions

Publication Details

Journal
Current Cardiology Reports
Published
2026-11-16
DOI
https://doi.org/10.1007/s11886-026-02450-9
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pulmonary Vein Isolation in Patients with Atrial Fibrillation: What Did We Learn from the SHAM Ablation Studies?

Tobias Uhe, Samira Beimel, Patrick Haag (née Dilk), Rolf Wachter et al.
Current Cardiology Reports
Atrial Fibrillation Management and Outcomes
article

Pulmonary Vein Isolation in Patients with Atrial Fibrillation: What Did We Learn from the SHAM Ablation Studies?

Tobias Uhe, Samira Beimel, Patrick Haag (née Dilk), Rolf Wachter, Nikolaos Dagres
article en

Abstract

Abstract Purpose of Review This review summarizes the findings and key lessons from sham-controlled trials of pulmonary vein isolation (PVI) in atrial fibrillation (AF). Recent Findings SHAM-PVI, PFA-SHAM, and PVI-SHAM-AF demonstrated lower AF recurrence and burden after PVI compared with sham. Quality of life improved after PVI in all trials, but PVI-SHAM-AF did not show superiority over sham because of similar improvements with sham, reflecting the contribution of nonspecific treatment effects such as expectancy, clinical attention and the Hawthorne effect. The trials demonstrate that invasive sham-controlled studies are feasible, safe, and can achieve blinding. Summary Reductions in AF recurrence and burden with PVI do not consistently translate into greater improvements in quality of life than sham. The contribution of nonspecific treatment effects may have been underestimated in previous trials. Further studies should characterize the relationship between AF burden and symptoms and identify patients most likely to derive symptomatic benefit from PVI.

Current Cardiology ReportsVol. 28(1)
Deutsches Herzzentrum der Charité (DE), Leipzig Heart Institute (DE), University Hospital Leipzig (DE), Charité - Universitätsmedizin Berlin (DE), Leipzig University (DE)
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon